2012
Immunotherapy for Cutaneous T-Cell Lymphoma
Modi B, Foss F, Edelson R, Girardi M. Immunotherapy for Cutaneous T-Cell Lymphoma. Contemporary Hematology 2012, 307-316. DOI: 10.1007/978-1-62703-170-7_18.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaToll-like receptor agonistsEffector T cell activityImmune effector mechanismsT cell activityGoal of therapyCytokine-based therapiesHistone deacetylase inhibitorsClinical responseMost patientsImmunotherapeutic approachesInterleukin-12Receptor agonistEffector mechanismsInterleukin-2Therapeutic approachesImmune functionDeacetylase inhibitorsTherapyCTCLPatientsLymphomaAttractive targetImmunotherapy
2004
Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma
Girardi M, Oppenheim D, Glusac EJ, Filler R, Balmain A, Tigelaar RE, Hayday AC. Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma. Journal Of Investigative Dermatology 2004, 122: 699-706. PMID: 15086556, DOI: 10.1111/j.0022-202x.2004.22342.x.Peer-Reviewed Original ResearchConceptsT cell responsesImmune responseCell responsesProtective anti-tumor effectTransplantable squamous cell carcinomaT cell-deficient miceAlphabeta T cell responsesCell-deficient miceT cell activityCellular immune responsesSquamous cell carcinomaΑβ T cell responsesSquamous cell carcinoma linesAlphabeta T cellsAnti-tumor effectsNK receptorsCell carcinomaT cellsFocal necrosesRAE-1Protective potentialTumor growthProtective responseStromal bedCell activity